Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Celon Pharma S.A. (CLN.WA)
PLN19.60
+0.14 (+0.72%)
PL WSE Healthcare Drug Manufacturers - Specialty & Generic
Address
ul. Ogrodowa 05-092
Lomianki, PL
Lomianki, PL
CEO
Maciej Wieczorek
Website
celonpharma.com
IPO
2017-02-17
ISIN PLCLNPH00015
Description
Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN19.60
+0.14 (+0.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8.8K
Beta
0.67
Float Shares
23.83M
Free Float %
44.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.97% | -2.15% | -3.53% | -9.69% | -5.53% | +0.49% | -6.82% | +28.13% | -56.20% | -7.99% | -7.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
19.60
Ratings Trend (MoM)
20% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.75
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+18.8% ★ Q1'26: +17.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-122.7% Q1'26: +751.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-39.6% Q1'26: -33.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-27.1% Q1'26: -17.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-15.7% Q1'26: -7.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.5% Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.81× Q1'26: 15.18× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
125.24M
est: 122.00M (+2.7%)
|
102.25M
est: 105.60M (-3.2%)
|
157.45M
est: 134.81M (+16.8%)
|
196.09M
est: 196.53M (-0.2%)
|
161.92M
est: 192.88M (-16.1%)
|
213.92M
est: 206.81M (+3.4%)
|
176.62M
est: 274.22M (-35.6%)
|
209.80M
est: 240.18M (-12.6%)
|
275.94M
249.82M – 308.33M
+14.9% YoY
|
302.40M
280.27M – 316.92M
+9.6% YoY
|
372.00M
340.77M – 402.81M
+23.0% YoY
|
| EBITDA |
55.85M
est: 15.37M (+263.4%)
|
26.84M
est: 13.30M (+101.7%)
|
30.37M
est: 16.98M (+78.8%)
|
27.81M
est: 24.76M (+12.3%)
|
9.32M
est: 24.30M (-61.6%)
|
32.71M
est: 16.01M (+104.3%)
|
14.96M
est: 21.23M (-29.5%)
|
-10.48M
est: 18.59M (-156.4%)
|
21.36M
19.34M – 23.87M
+14.9% YoY
|
23.41M
21.70M – 24.53M
+9.6% YoY
|
28.80M
26.38M – 31.18M
+23.0% YoY
|
| EBIT |
38.64M
est: -14.64M (+363.9%)
|
6.22M
est: -12.67M (+149.1%)
|
-4.17M
est: -16.18M (+74.2%)
|
-13.53M
est: -23.59M (+42.6%)
|
-34.78M
est: -23.15M (-50.2%)
|
-17.31M
est: -34.91M (+50.4%)
|
-36.90M
est: -46.30M (+20.3%)
|
-56.76M
est: -40.55M (-40.0%)
|
-46.59M
-52.05M – -42.18M
-14.9% YoY
|
-51.05M
-53.50M – -47.32M
-9.6% YoY
|
-62.80M
-68.00M – -57.53M
-23.0% YoY
|
| Net Income |
29.70M
est: 36.77M (-19.2%)
|
11.93M
est: 21.01M (-43.2%)
|
-917.0K
est: 30.73M (-103.0%)
|
-11.61M
est: -10.50M (-10.5%)
|
-39.28M
est: -36.81M (-6.7%)
|
-28.12M
est: -45.48M (+38.2%)
|
-34.45M
est: 25.29M (-236.2%)
|
-79.36M
est: -55.97M (-41.8%)
|
-29.62M
-33.66M – -25.58M
+47.1% YoY
|
4.04M
1.12M – 6.96M
+113.6% YoY
|
21.53M
19.19M – 23.86M
+432.9% YoY
|
| SGA |
18.34M
est: 42.10M (-56.4%)
|
62.36M
est: 36.44M (+71.1%)
|
83.44M
est: 46.52M (+79.4%)
|
90.11M
est: 67.82M (+32.9%)
|
13.10M
est: 66.56M (-80.3%)
|
111.12M
est: 49.45M (+124.7%)
|
23.94M
est: 65.56M (-63.5%)
|
—
est: 57.42M (-100.0%)
|
65.97M
59.73M – 73.72M
+14.9% YoY
|
72.30M
67.01M – 75.77M
+9.6% YoY
|
88.94M
81.47M – 96.31M
+23.0% YoY
|
| EPS |
0.66
est: 0.70 (-5.7%)
|
0.27
est: 0.40 (-32.5%)
|
-0.02
est: 0.59 (-103.5%)
|
-0.25
est: -0.20 (-25.0%)
|
-0.77
est: -0.69 (-11.6%)
|
-0.55
est: -0.89 (+38.3%)
|
-0.66
est: 0.47 (-240.4%)
|
-1.47
est: -1.04 (-41.3%)
|
-0.55
-0.63 – -0.48
+47.1% YoY
|
0.08
0.02 – 0.13
+113.6% YoY
|
0.40
0.36 – 0.44
+433.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
16.55M
OE per share TTM
0.30
Owner's Yield
1.52%
Maintenance CapEx ratio
0.30%
Maint CapEx / Avg PPE
177.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 7 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 57.9K | 0.65% |
| 2 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 3.3K | 0.07% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 41.2K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 50.1K | 0.28% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 8.3K | 0.29% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 399.78 | 0.44% |
| 7 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 147.12 | 0.56% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-101.0K
Shares Outstanding
53.86M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bartosz Szalek | Chief Financial Officer & Member of the Management Board | 652.9K | — |
| Maciej Wieczorek | Chief Executive Officer & President of Management Board | 78.0K | — |
| Malgorzata Stokrocka | CDOO & Member of Management Board | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLN.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
